Traumatic brain injury (TBI) is a major cause of death and permanent disability. Systemic hypothermia, a treatment used in TBI for many decades, has recently been found to be associated with neutral or unfavourable clinical outcomes despite apparently promising preclinical research. Systematic review and meta-analysis is a tool to summarize literature and observe trends in experimental design and quality that underpin its general conclusions. Here we aim to use these techniques to describe the use of hypothermia in animal TBI models, collating data relating to outcome and both study design and quality. From here we intend to observe correlations between features and attempt to explain any discrepancies found between animal and clinical data. This protocol describes the relevant methodology in detail.
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hypothermia, meta-analysis, systematic review, traumatic brain injury 1 | BACKGROUND Traumatic brain injury (TBI) represents a significant challenge in healthcare across the world: it is the leading cause of death and permanent disability in young adults and incidence is increasing. 2, 3 Despite significant progress in the understanding of pathophysiology and developments of novel experimental treatments, there have been no consequential therapies successfully translated into clinical practice. Similarly, many of the treatments accepted as standard care have weak evidence bases. [4] [5] [6] [7] Hypothermia is a therapy well established in the neuro-intensive care, having been commonplace in TBI management for half a century. It is based on the underlying principle that hypothermia controls dangerously elevated intracranial pressure and mediates damage to neural tissue from hypoxic and other metabolic mechanisms. However there is increasing evidence that, in TBI patients, induced hypothermia is at least as effective at controlling intracranial pressure as This protocol is based on the Systematic Review Protocol for Animal Intervention Studies ( other medical therapies, however, importantly it is associated with neutral or unfavourable long term outcomes. 4, 8, 9 These findings contradict a consensus that hypothermia in in vivo studies is effective. We therefore seek to describe the preclinical literature using systematic review and meta-analysis, and aim to provide an explanation as to why this discrepancy might exist. We hypothesize that the preclinical dataset will consist of a large number of small, heterogeneous studies with differences in efficacy associated with features relating to both risk of bias (randomization, blinding, publication bias) as well as experimental design features (features of animals used, TBI model, hypothermia treatment and control group temperature).
| METHODS

| Literature search
We will search PubMed, MEDLINE and EMBASE using the search strategies below: Searches will be limited to animals using previously developed filters.
10,11
| Study selection
We will include studies that satisfy the following inclusion criteria: We will first screen titles and abstracts, excluding studies not relating to an animal model of TBI. Subsequently we will screen full articles of remaining studies and apply the above selection criteria.
Two authors will screen studies (TCH/RW) and differences will be resolved by discussion. In cases of no consensus and third reviewer (MRM) will be consulted.
There will be no language or date restrictions and all peer review articles, conference abstracts and other modalities of publication will be accepted if sufficient information is provided for inclusion.
Reviews and clinical papers will be excluded.
| Methodological quality and study bias
We will assess risk of bias according to a modified scale developed by the CAMARADES group for stroke studies: 
| Data extraction
We will use neurobehavioural outcome scores as our primary outcome.
Secondary outcome measures: we will include pathological indicators such as contusion/haematoma size, physiological measurements such as intracranial pressure and biochemical markers of oedema, cell death or axonal damage.
We will include all studies comparing a hypothermic treatment group (induced or permissive) with a normothermic or hyperthermic control (induced or natural disease course). For studies reporting more than one group we will include all comparisons, correcting for the number of control groups as appropriate.
Relating to study design, we will extract the information outlined in Table 2 .
| Data collation and analysis
Data will be extracted in duplicate by TCH and RW. Differences in extracted data will be resolved by discussion. We will extract data from publications via text, if available, or by measurement from graphs with a digital screen ruler. Should this information not be immediately clear from the publication we will contact the authors directly. We will correct for the multiple use of a single control group by dividing the number of animals in each control group by the number of times represented in the dataset.
For neurobehavioural outcomes, we will pool data for analysis using the DerSimonian and Laird random-effects model, as we expect a large degree of methodological variability between studies, and assess for the presence of heterogeneity using the I 2 statistic. We will then attempt a multi-variable metaregression to investigate relationships between reported efficacy and the study quality and design features highlighted above, for variables in which there are 10 studies or more in every group. In sensitivity analysis, we will perform a univariate metaregression.
For secondary outcomes, namely contusion size, ICP, mortality and biochemical markers we intend to first perform a frequency analysis to describe the number of times each outcome or molecule is reported in the literature. Following this, we will calculate efficacy estimates (via a random-effects model) for those outcomes with
We will search for publication bias using funnel plots, Egger regression and p-curve analysis. 13 Changes in this analysis plan will be announced and reported in the study publication subsequently.
